PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Endometrial cancer
Immune checkpoint inhibitor
Immunotherapy
PARP
PD-1
PD-L1
Targeted therapy
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
19
11
2019
revised:
20
04
2020
accepted:
20
04
2020
pubmed:
5
6
2020
medline:
16
7
2020
entrez:
5
6
2020
Statut:
ppublish
Résumé
The prognosis of recurrent or metastatic endometrial cancer is poor, with five-year survival of only 10-20 %. First-line therapy consists of either platinum-based chemotherapy or hormonal therapy. No standard subsequent-line therapy has been identified. In recent years, significant progress has been made in the knowledge on underlying molecular biology of endometrial cancer and potential targets for therapy have been identified. Targeted therapies as poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy as PD-1/PD-L1 checkpoint inhibitors have the potential to be effective against specific subtypes of endometrial cancer. Preclinical studies have shown that combining these agents may result in a synergistic effect. In this review, we focus on the molecular basis of checkpoint inhibition and targeted therapy as PARP inhibition in endometrial cancer and summarize available clinical data, and ongoing and planned clinical trials that investigate these agents as mono- or combination therapies in endometrial cancer and where relevant, other gynecological cancers.
Identifiants
pubmed: 32497971
pii: S1040-8428(20)30111-6
doi: 10.1016/j.critrevonc.2020.102973
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Programmed Cell Death 1 Receptor
0
Proteins
0
poly(ADP)-ribosylated proteins
0
Poly Adenosine Diphosphate Ribose
26656-46-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102973Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr JR Kroep has received a study grant from AstraZeneca and steering committee member AstraZeneca, Novartis, Pfizer and Tesaro/GSK.